Clinical Trial: Letermovir vs Valganciclovir in CMV R+ Kidney Transplant

U.S., May 7 -- ClinicalTrials.gov registry received information related to the study (NCT07571135) titled 'Letermovir vs Valganciclovir in CMV R+ Kidney Transplant' on April 29.

Brief Summary: The purpose of this study is to find out whether letermovir can help prevent cytomegalovirus (CMV) infection in kidney transplant recipients who are CMV seropositive. To do this, researchers will compare patients who received letermovir with a group of historical patients who received valganciclovir ("mini dose"). Both groups will be on CMV prophylaxis drug for 90 days post-transplant.

The main question the study wants to answer is:

* Does letermovir work as well as valganciclovir in preventing CMV infections during the first 12 months after a kidn...